Mallinckrodt has acquired InfaCare in a deal worth up to $425 million. InfaCare’s developmental product stannsoporfin, a heme oxygenase inhibitor, is under investigation for its potential to reduce the production of bilirubin, the elevation of which can contribute to serious consequences in infants. In July 2016 InfaCare and the U.S. FDA reached agreement that a new drug application (NDA) could be filed for stannsoporfin after a positive Phase 2(b) trial as its pivotal study and data fr...